SIDHU MANINDER K.,ANDERSON ANNALIESA SYBIL,DONALD ROBERT G. K.,JANSEN KATHRIN UTE,KALYAN NARENDER K.,MININNI TERRI L.,MORAN JUSTIN KEITH,RUPPEN MARK E.,FLINT MICHAEL JAMES
申请号：
NZ61603512
公开号：
NZ616035A
申请日:
2012.04.20
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed is an immunogenic composition comprising a mutant Clostridium difficile toxin A, which comprises a wild-type Clostridium difficile toxin A having (a) a glucosyltransferase domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 101, 269, 272, 285, 287, 460, 462, 541, or 542, according to the numbering of SEQ ID NO: 1 and (b) a cysteine protease domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 700, 589, 655, or 543, according to the numbering of SEQ ID NO: 1, relative to the corresponding wild-type Clostridium difficile toxin A and a diluent. Also disclosed is an immunogenic composition comprising a mutant Clostridium difficile toxin B, which comprises a wild-type Clostridium difficile toxin B having (a) a glucosyltransferase domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 102, 286, 288, 270, 273, 384, 461, 463, 520, or 543, according to the numbering of SEQ ID NO: 2 and (b) a cysteine protease domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 698, 653, 587, or 544, according to the numbering of SEQ ID NO: 2, relative to the corresponding wild-type Clostridium difficile 5 toxin B and a diluent.
